| Literature DB >> 34055596 |
Christian Bäumer1,2,3,4, Sandija Plaude1,2, Dalia Ahmad Khalil1,2,5, Dirk Geismar1,2,3,5, Paul-Heinz Kramer1,2, Kevin Kröninger4, Christian Nitsch4, Jörg Wulff1,2, Beate Timmermann1,2,3,5.
Abstract
Proton therapy makes use of the favorable depth-dose distribution with its characteristic Bragg peak to spare normal tissue distal of the target volume. A steep dose gradient would be desired in lateral dimensions, too. The widespread spot scanning delivery technique is based, however, on pencil-beams with in-air spot full-widths-at-half-maximum of typically 1 cm or more. This hampers the sparing of organs-at-risk if small-scale structures adjacent to the target volume are concerned. The trimming of spot scanning fields with collimating apertures constitutes a simple measure to increase the transversal dose gradient. The current study describes the clinical implementation of brass apertures in conjunction with the pencil-beam scanning delivery mode at a horizontal, clinical treatment head based on commercial hardware and software components. Furthermore, clinical cases, which comprised craniopharyngiomas, re-irradiations and ocular tumors, were evaluated. The dosimetric benefits of 31 treatment plans using apertures were compared to the corresponding plans without aperture. Furthermore, an overview of the radiation protection aspects is given. Regarding the results, robust optimization considering range and setup uncertainties was combined with apertures. The treatment plan optimizations followed a single-field uniform dose or a restricted multi-field optimization approach. Robustness evaluation was expanded to account for possible deviations of the center of the pencil-beam delivery and the mechanical center of the aperture holder. Supplementary apertures improved the conformity index on average by 15.3%. The volume of the dose gradient surrounding the PTV (evaluated between 80 and 20% dose levels) was decreased on average by 17.6%. The mean dose of the hippocampi could be reduced on average by 2.9 GyRBE. In particular cases the apertures facilitated a sparing of an organ-at-risk, e.g. the eye lens or the brainstem. For six craniopharyngioma cases the inclusion of apertures led to a reduction of the mean dose of 1.5 GyRBE (13%) for the brain and 3.1 GyRBE (16%) for the hippocampi.Entities:
Keywords: aperture; brain tumors; ocular tumors; pencil-beam scanning; proton therapy; quality assurance; radiation protection
Year: 2021 PMID: 34055596 PMCID: PMC8149965 DOI: 10.3389/fonc.2021.599018
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Pencil-beam scanning in-air spot characteristics of the treatment plans of the current study.
| Energy | σ | Comment |
|---|---|---|
| (MeV) | (mm) | |
| 100 | 8.1 | minimum energy among all cases |
| 110 | 7.4 | median of the lowest energy of all cases |
| 130 | 6.5 | median energy of all cases |
| 150 | 5.3 | median of the highest energy of all cases |
| 170 | 4.6 | maximum energy among all cases |
Fields were applied with the IBA universal nozzle of the fixed-beam treatment room of WPE. σ refers to the standard deviation derived from a fit of a Gaussian distribution to the lateral spot profile. Proton energy values of the layers were rounded, because spot characteristics were measured in the isocenter plane in steps of 10 MeV in the clinical commissioning.
Overview of all cases which were treated with PBS-with-apertures and which were evaluated in the current study.
| Localization | Diagnosis | Number of patients/retreatments | Average age (years) | VPTV (cm3) |
|---|---|---|---|---|
| Orbital tumors | Retinoblastoma | 3 | 3 | 9.0 |
| Embryonal Rhabdomyosarcoma | 1 | 12 | 16.2 | |
| Optic nerve Glioma | 1 | 14 | 113.8 | |
| Choroidal Melanoma | 1 | 51 | 8.6 | |
| Choroidal Hemangioma | 1 | 20 | 12.0 | |
| Base of skull tumors | Optic Posterior Pathway Glioma | 1 | 8 | 67.0 |
| Brainstem Glioma | 1 | 2 | 31.5 | |
| Intracranial tumors | Clivuschordoma | 1 | 58 | 20.9 |
| (infratentorial) | Ependymoma | 6/2 | 9 | 22.5 |
| Atypical Teratoid Rhabdoid tum. | 1/1 | 6 | 30.8 | |
| (supratentorial, midline) | Craniopharyngioma | 7/1 | 12 | 97.6 |
| Neurocytoma | 1 | 20 | 27.0 | |
| Germ Cell tumor | 3/1 | 8 | 52.4 | |
| Astrocytoma | 1 | 37 | 38.7 | |
| (supratentorial, unilateral) | Astrocytoma | 2 | 42 | 173.7 |
For patient groups the age and the average volume of the PTV (VPTV) are listed.
Figure 1Beams-eye view of a treatment field of the uncollimated plan (A) and the treatment plan with apertures (B). The red contour indicates the PTV. The pink (blue) and green (magenta) contours indicate the eye (lens). The dark gray hatched area visualizes the brass of the aperture. The dark gray annular ring represents the snout holder. Orange crosses and circles indicate the centers of individual pencil-beam scanning spots of one of the energy layers. The dose distribution of the treatment plan is shown in .
Figure 6Transversal CT slices overlaid with a colorwash representation of the dose distribution of the uncollimated plan (A) and the plan with apertures (B) for the treatment of an opticus glioma. The screenshots of the treatment planning in RayStation show the dose sparing of the eye lenses, which are indicated by the blue and magenta contours. (C) shows the dose difference between the plans. The beams eye view of one of the treatment fields is shown in .
Overview of quality assurance procedures. “MPE review” refers to the clinical release of a treatment plan by a certified medical physicist (“medical physics expert”).
| Parameter | Warning level | Tolerance level | Test interval | Test device/comment |
|---|---|---|---|---|
| Co-incidence of coord. of | 0.5 mm | 1 mm | monthly | Lynx2D (EBT3 as alternative) |
| Co-incidence of coord. of | – | 1.5 mm | daily | spot positioning test |
| Co-incidence of aperture & PBS | – | 1 mm | monthly | Lynx2D |
| Relative spot position | – | <5% of spots >1 mm | monthly | Lynx2D |
| – | max 1.5 mm | |||
| Outline of fabricated aperture | – | 1 mm | field-specific | visual test with print-out |
| Dose plane of fields: γ -test | γ < 1 | γ <1 | field-specific | DigiPhant; |
| for <95% | for <90% | global γ 3%/2 mm, | ||
| Number of apertures correct | – | pass/fail | field-specific | Python script; MPE review |
EBT3 is a radiochromic film of the vendor Ashland. Lynx2D is a scintillation screen with electronic readout (IBA dosimetry). “coord.” is used as abbreviation for “coordinates”. The Python script runs within the RayStation treatment planning system.
Figure 2Percentage difference of ΔV20-80% and CI 50% between PBS plans with and without collimating apertures visualized in a box-whisker plot. ΔV20-80%, volume between 20 and 80% isodose lines; CI 50%, conformity index of 50% isodose line; PBS, uncollimated pencil beam scanning; PBS-A, pencil beam scanning with apertures. The boxes (whisker) indicate the 25th and 75th percentiles (1.5 times interquartile range). Data points outside the three times (1.5 and three times) the interquartile range are indicated by open circles (plus symbol). Median values are indicated by red lines.
Percentage difference in ΔV20-80% and CI 50% for PBS-with-aperture plans compared with uncollimated PBS plans.
| Tumor entity | Vol. 20–80% | CI-50% |
|---|---|---|
| Orbital tumors | −27.0% | 18.0% |
| Craniopharyngioma | −13.6% | 13.6% |
| Ependymoma | −16.0% | 8.0% |
| Astrocytoma | −3.3% | 7.8% |
| Retreatment | −30.4% | 21.0% |
| Other brain tumors | −7.7% | 17.3% |
Figure 3Summary of the mean dose (Dmean) reduction for OARs using PBS-with-apertures (“PBS-A”) indicated by circles. The boxes show the full range of achieved reductions. The shown structures are Thal, thalamus; Hica, hippocampus; BrSt, brainstem; OpNe, eye lens, optical nerve; TeLo, temporal lobe.
Figure 4Dose reduction to organs-at-risk (OAR) for craniopharyngioma cases comparing plans with aperture (“PBS-A”) with uncollimated plans (“PBS”). Percentage difference of Dmean for organs-at-risk between the plans with and without apertures. The boxes show the full range of achieved reductions. The shown structures are Thal, thalamus; HiCa, hippocampus; BrSt, brainstem; OpNe, optical nerve; TeLo, temporal lobe; and brain.
Figure 5Sagittal CT slices overlaid with a colorwash representation of the dose distribution of the uncollimated plan (A) and the treatment plan with apertures (B) for the treatment of a suprasellar craniopharyngioma. The screenshots of the treatment planning in RayStation show the dose sparing of the left thalamus, which is indicated by the light blue contour. (C) shows the dose difference between the plans.
Figure 7Use of PBS-with-apertures for one of the retreatment cases (metastasis of an atypical teratoid rhabdoid tumor in the fossa posterior). Screenshots of treatment planning in RayStation are shown. Dose distributions in a transversal plane are shown as colorwash (A–C) PBS-with-apertures, uncollimated PBS plan, dose difference between PBS-with-apertures and uncollimated PBS plans; (D) dose volume histogram showing the difference for the brainstem and the target volumes between uncollimated (dashed line) and collimated (solid line) plans. PTV/CTV/brainstem is contoured with an orange/light blue/cyan line.